Darius Moradpour

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


441 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ...
 
HEV ORF2 protein-antibody complex deposits are associated with glomerulonephritis in hepatitis E with reduced immune status.
Leblond A.L., Helmchen B., Ankavay M., Lenggenhager D., Jetzer J., Helmchen F., Yurtsever H., Parrotta R., Healy M.E., Pöschel A. et al., 2024/10/14. Nature communications, 15 (1) p. 8849. Peer-reviewed.
 
Cancer du pancréas : une épidémie oncologique en devenir ?
Frossard J.L., Moradpour D., 2024/08/28. Revue medicale suisse, 20 (884) pp. 1439-1440. Peer-reviewed.
 
Maladie hépatique associée à la chirurgie de Fontan [Fontan associated liver disease]
Shams T., Salvador Nunes L., Schmidt S., Gast E., Sempoux C., Moradpour D., Di Bernardo S., Sekarski N., Rutz T., Ladouceur M. et al., 2024/08/28. Revue medicale suisse, 20 (884) pp. 1469-1475. Peer-reviewed.
Trends in the burden of hospitalised patients with cirrhosis in Switzerland: a cross-sectional study of cirrhosis-related hospitalisations between 1998 and 2020.
Favre-Bulle T., Moradpour D., Marques-Vidal P., Vaucher J., 2024/08/24. BMJ open, 14 (8) pp. e081822. Peer-reviewed.
Direct oral anticoagulants in cirrhosis: Rationale and current evidence.
Pereira Portela C., Gautier L.A., Zermatten M.G., Fraga M., Moradpour D., Bertaggia Calderara D., Aliotta A., Veuthey L., De Gottardi A., Stirnimann G. et al., 2024/08. JHEP reports, 6 (8) p. 101116. Peer-reviewed.
High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder.
Coukos A., Saglietti C., Sempoux C., Haubitz M., Greuter T., Mittaz-Crettol L., Maurer F., Mdawar-Bailly E., Moradpour D., Alberio L. et al., 2024/08/01. Hepatology communications, 8 (8). Peer-reviewed.
 
Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection.
Radu P., Becchetti C., Schropp J., Schmid P., Künzler-Heule P., Mertens J., Moradpour D., Müllaupt B., Semela D., Negro F. et al., 2024/07/18. Cancers, 16 (14). Peer-reviewed.
Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis.
Moschouri E., Salemme G., Baserga A., Cerny A., Deibel A., Müllhaupt B., Meier M.A., Bernsmeier C., Ongaro M., Negro F. et al., 2024/06/24. Swiss medical weekly, 154 (6) p. 3698. Peer-reviewed.
Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation.
Xu Z.M., Gnouamozi G.E., Rüeger S., Shea P.R., Buti M., Chan H.L., Marcellin P., Lawless D., Naret O., Zeller M. et al., 2024/06/06. American journal of human genetics, 111 (6) pp. 1018-1034. Peer-reviewed.
 
A genome-wide CRISPR/Cas9 screen identifies a role for Rab5A and early endosomes in hepatitis E virus replication.
Oechslin N., Da Silva N., Ankavay M., Moradpour D., Gouttenoire J., 2023/12/26. Proceedings of the National Academy of Sciences of the United States of America, 120 (52) pp. e2307423120. Peer-reviewed.
Elevated liver function tests in a patient with breast cancer.
Neftel C., Zaman K., Chtioui H., Moradpour D., Sempoux C., Fraga M., 2023/09. Journal of hepatology, 79 (3) pp. e109-e111. Peer-reviewed.
 
Traitements à siRNA : état des lieux et perspectives [siRNA therapeutics : Current options and perspectives]
Neftel C., Moradpour D., 2023/08/30. Revue medicale suisse, 19 (839) pp. 1538-1542. Peer-reviewed.
Body composition and short-term mortality in patients critically ill with acute-on-chronic liver failure.
Mangana Del Rio T., Sacleux S.C., Vionnet J., Ichaï P., Denys A., Schneider A., Coilly A., Fraga M., Wetzel A., Koerfer J. et al., 2023/08. JHEP reports, 5 (8) p. 100758. Peer-reviewed.
Expanding the Hepatitis E Virus Toolbox: Selectable Replicons and Recombinant Reporter Genomes.
Oechslin N., Ankavay M., Moradpour D., Gouttenoire J., 2023/03/28. Viruses, 15 (4) p. 869. Peer-reviewed.
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
La résection endoscopique va-t-elle suppléer la chirugie ?
Frossard J.L., Moradpour D., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1575-1576. Peer-reviewed.
Métabolisme et suivi thérapeutique de l’azathioprine en gastroentérologie et hépatologie [Metabolism and therapeutic monitoring of azathioprine in gastroenterology and hepatology]
Bianchetti D., Salvador Nunes L., André P., Schoepfer A., Moradpour D., Chtioui H., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1588-1593. Peer-reviewed.
Syndrome des télomères courts chez l’adulte : une entité rare qu’il faut savoir évoquer [Short telomere syndrome in adults: a rare entity that should be evoked]
Coukos A., Daccord C., Lazor R., Blum S., Naveiras O., Unger S., Vionnet J., Gaide O., Koutsokera A., Moschouri E. et al., 2022/08/31. Revue medicale suisse, 18 (793) pp. 1606-1613. Peer-reviewed.
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction.
Artru F., Vietti-Violi N., Sempoux C., Vieira Barbosa J., Becce F., Sah N., Marot A., Deltenre P., Moschouri E., Fraga M. et al., 2022/08. JHEP reports, 4 (8) p. 100511. Peer-reviewed.
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.
Herderschee J., Heinonen T., Fenwick C., Schrijver I.T., Ohmiti K., Moradpour D., Cavassini M., Pantaleo G., Roger T., Calandra T. et al., 2022/04. Clinical microbiology and infection, 28 (4) pp. 611.e1-611.e7. Peer-reviewed.
Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis.
Kasmi S., Artru F., Barbosa J.V., Deibel A.R., Favre L., Peuble C., Saouli A.C., Goossens N., Müllhaupt B., Pascual M. et al., 2022/02/28. Swiss medical weekly, 152 pp. w30138. Peer-reviewed.
Hepatitis E virus RNA-dependent RNA polymerase is involved in RNA replication and infectious particle production.
Oechslin N., Da Silva N., Szkolnicka D., Cantrelle F.X., Hanoulle X., Moradpour D., Gouttenoire J., 2022/01. Hepatology, 75 (1) pp. 170-181. Peer-reviewed.
Hépatite autoimmune : mise au point 2021 [Autoimmune hepatitis: 2021 update]
Stamm G.M., Sempoux C., Fraga M., Comte D., Aubert V., Moradpour D., Vionnet J., Moschouri E., 2021/09/01. Revue medicale suisse, 17 (748) pp. 1457-1463. Peer-reviewed.
Impact du Covid-19 sur la gastroentérologie et l’hépatologie.
Schoepfer A., Frossard J.L., MORADPOUR D., 2021/09/01. Revue medicale suisse, 17 (748) p. 1435. Peer-reviewed.
Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue.
Vieira Barbosa J., Müllhaupt B., Brunner F., Filipowicz Sinnreich M., Semela D., Montani M., Cathomas G., Neuweiler J., Gouttenoire J., Artru F. et al., 2021/04/26. Swiss medical weekly, 151 pp. w20502. Peer-reviewed.
Gastroentérologie et hépatologie [Advances in gastroenterology and hepatology 2020]
Artru F., Fraga M., Godat S., Schoepfer A.M., Moradpour D., 2021/01/13. Revue medicale suisse, 17 (720-1) pp. 29-32. Peer-reviewed.
Case Report: SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis.
Filippidis P., van Ouwenaller F., Cerutti A., Geiger-Jacquod A., Sempoux C., Pantaleo G., Moradpour D., Lamoth F., 2021. F1000Research, 10 p. 400. Peer-reviewed.
Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
Vieira Barbosa J., Sahli R., Aubert V., Chaouch A., Moradpour D., Fraga M., 2021. PloS one, 16 (4) pp. e0250347. Peer-reviewed.
The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition.
Lenggenhager D., Pawel S., Honcharova-Biletska H., Evert K., Wenzel J.J., Montani M., Furrer E., Fraga M., Moradpour D., Sempoux C. et al., 2021/01. Modern pathology, 34 (1) pp. 233-248. Peer-reviewed.
COVID-19 in an international European liver transplant recipient cohort.
Becchetti C., Zambelli M.F., Pasulo L., Donato M.F., Invernizzi F., Detry O., Dahlqvist G., Ciccarelli O., Morelli M.C., Fraga M. et al., 2020/10. Gut, 69 (10) pp. 1832-1840. Peer-reviewed.
Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis.
Fraga M., Moradpour D., Artru F., Romailler E., Tschopp J., Schneider A., Chtioui H., Neerman-Arbez M., Casini A., Alberio L. et al., 2020/10. Journal of hepatology, 73 (4) pp. 967-970. Peer-reviewed.
 
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
Dietz J., Kalinina O.V., Vermehren J., Peiffer K.H., Matschenz K., Buggisch P., Niederau C., Schattenberg J.M., Müllhaupt B., Yerly S. et al., 2020/10. Journal of viral hepatitis, 27 (10) pp. 974-986. Peer-reviewed.
Adénomes hépatocellulaires : update 2020 [Hepatocellular adenoma: update 2020]
Romailler E., Schmidt Kobbe S., Moradpour D., Sempoux C., 2020/09/02. Revue medicale suisse, 16 (704) pp. 1554-1559. Peer-reviewed.
COVID-19 et hépatologie
Negro F., Moradpour D., 2020/09/02. Revue medicale suisse, 16 (704) pp. 1535-1536. Peer-reviewed.
Early TIPS : une revue pratique après 15 ans d’évidence scientifique [Early TIPS: a practical review after 15 years of scientific evidence]
Shams T., Moschouri E., Denys A., Moradpour D., Fraga M., Artru F., 2020/09/02. Revue medicale suisse, 16 (704) pp. 1548-1553. Peer-reviewed.
All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS).
Roelens M., Bertisch B., Moradpour D., Cerny A., Semmo N., Schmid P., Müllhaupt B., Clerc O., Semela D., Junker C. et al., 2020/08. Open forum infectious diseases, 7 (8) pp. ofaa308. Peer-reviewed.
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Zermatten M.G., Fraga M., Calderara D.B., Aliotta A., Moradpour D., Alberio L., 2020/08. JHEP reports, 2 (4) p. 100120. Peer-reviewed.
Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis.
Artru F., Alberio L., Moradpour D., Stalder G., 2020/07/07. BMJ case reports, 13 (7) pp. e236815. Peer-reviewed.
Combined Lung and Liver Transplantation for Short Telomere Syndrome.
Moschouri E., Vionnet J., Giostra E., Daccord C., Lazor R., Sciarra A., Letovanec I., Sempoux C., Gonzalez M., Unger S. et al., 2020/06. Liver transplantation, 26 (6) pp. 840-844. Peer-reviewed.
 
Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis.
Zermatten M.G., Fraga M., Moradpour D., Bertaggia Calderara D., Aliotta A., Stirnimann G., De Gottardi A., Alberio L., 2020/06. Hepatology, 71 (6) pp. 2135-2148. Peer-reviewed.
On the Host Side of the Hepatitis E Virus Life Cycle.
Oechslin N., Moradpour D., Gouttenoire J., 2020/05/22. Cells, 9 (5) p. 1294. Peer-reviewed.
 
Hepatitis E virus finds its path through the gut.
Oechslin N., Moradpour D., Gouttenoire J., 2020/05. Gut, 69 (5) pp. 796-798. Peer-reviewed.
Infection à SARS-CoV-2 et transplantation d’organes solides [SARS-CoV-2 infection and solid organ transplantation]
Golshayan D., Aubert J.D., Hullin R., Moradpour D., Venetz J.P., Manuel O., Pascual M., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 815-818. Peer-reviewed.
 
Hepatitis A and E - Differences and commonalities.
Gotlieb N., Moradpour D., Shouval D., 2020/03. Journal of hepatology, 72 (3) pp. 578-580. Peer-reviewed.
 
Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?
Bertisch B., Brezzi M., Negro F., Müllhaupt B., Ottiger C., Künzler-Heule P., Schmid P., Giudici F., Clerc O., Moriggia A. et al., 2020/02/03. Clinical infectious diseases, 70 (4) pp. 653-659. Peer-reviewed.
Neurologic complications of acute hepatitis E virus infection.
Ripellino P., Pasi E., Melli G., Staedler C., Fraga M., Moradpour D., Sahli R., Aubert V., Martinetti G., Bihl F. et al., 2020/01. Neurology, 7 (1) pp. e643. Peer-reviewed.
OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
Tran HTL, Morikawa K., Anggakusuma A, Zibi R., Thi VLD, Penin F., Heim M.H., Quadroni M., Pietschmann T., Gouttenoire J. et al., 2020. PloS one, 15 (7) pp. e0236447. Peer-reviewed.
Recombinant Hepatitis E Viruses Harboring Tags in the ORF1 Protein.
Szkolnicka D., Pollán A., Da Silva N., Oechslin N., Gouttenoire J., Moradpour D., 2019/10/01. Journal of virology, 93 (19) pp. e00459-19. Peer-reviewed.
L’hépatologie opère sa mue.
Moradpour D., Frossard J.L., 2019/08/28. Revue medicale suisse, 15 (660) pp. 1475-1476. Peer-reviewed.
 
Suivi ambulatoire du patient transplanté hépatique: le rôle essentiel du médecin généraliste [Outpatient follow-up of liver transplant recipients: the essential role of the general practitioner]
Henchoz S., Fraga M., Saouli A.C., Elkrief L., Berney T., Toso C., Compagnon P., Andres A., Denys A., Pascual M. et al., 2019/08/28. Revue medicale suisse, 15 (660) pp. 1488-1495. Peer-reviewed.
Syndrome d’Alagille [Alagille Syndrome]
Wakim El-Khoury J., Venetz J.P., Rutz T., Sciarra A., Unger S., Sempoux C., Moradpour D., Fraga M., 2019/08/28. Revue medicale suisse, 15 (660) pp. 1506-1510. Peer-reviewed.
 
Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents.
Terziroli Beretta-Piccoli B., Di Bartolomeo C., Deleonardi G., Grondona A.G., Silvestri T., Tesei C., Melidona L., Cerny A., Mertens J., Semmo N. et al., 2019/08. Journal of autoimmunity, 102 pp. 89-95. Peer-reviewed.
Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Fraga M., Gouttenoire J., Sahli R., Chtioui H., Marcu C., Pascual M., Moradpour D., Vionnet J., 2019/05/24. BMC gastroenterology, 19 (1) p. 76. Peer-reviewed.
 
Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland.
Sahli R., Fraga M., Semela D., Moradpour D., Gouttenoire J., 2019/05. Journal of hepatology, 70 (5) pp. 1023-1025. Peer-reviewed.
 
Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients.
Asgari S., Chaturvedi N., Scepanovic P., Hammer C., Semmo N., Giostra E., Müllhaupt B., Angus P., Thompson A.J., Moradpour D. et al., 2019/02. Journal of viral hepatitis, 26 (2) pp. 271-277. Peer-reviewed.
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
Brezzi M., Bertisch B., Roelens M., Moradpour D., Terziroli Beretta-Piccoli B., Semmo N., Müllhaupt B., Semela D., Negro F., Keiser O. et al., 2019. PloS one, 14 (6) pp. e0218706. Peer-reviewed.
Hepatic manifestations of Wilson's disease: 12-year experience in a Swiss tertiary referral centre.
Vieira Barbosa J., Fraga M., Saldarriaga J., Hiroz P., Giostra E., Sempoux C., Ferenci P., Moradpour D., 2018/12/17. Swiss medical weekly, 148 pp. w14699. Peer-reviewed.
Palmitoylation mediates membrane association of hepatitis E virus ORF3 protein and is required for infectious particle secretion.
Gouttenoire J., Pollán A., Abrami L., Oechslin N., Mauron J., Matter M., Oppliger J., Szkolnicka D., Dao Thi V.L., van der Goot F.G. et al., 2018/12. PLoS pathogens, 14 (12) pp. e1007471. Peer-reviewed.
 
Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs.
Saleh M., Welsch C., Cai C., Döring C., Gouttenoire J., Friedrich J., Haselow K., Sarrazin C., Badenhoop K., Moradpour D. et al., 2018/10. The Journal of steroid biochemistry and molecular biology, 183 pp. 142-151. Peer-reviewed.
Cholangite biliaire primitive : mise à jour [Primary biliary cholangitis : an update]
Vieira Barbosa J., Vionnet J., Sciarra A., Sempoux C., Aubert V., Moradpour D., Fraga Christinet M., 2018/08/29. Revue medicale suisse, 14 (616) pp. 1489-1494. Peer-reviewed.
Clostridium – si difficile et si onéreux
Frossard J.L., Moradpour D., 2018/08/29. Revue medicale suisse, 14 (616) p. 1483. Peer-reviewed.
 
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review.
Goossens N., de Vito C., Mangia A., Clément S., Cenderello G., Barrera F., D'Ambrosio R., Coppola N., Zampino R., Stanzione M. et al., 2018/08. Journal of viral hepatitis, 25 (8) pp. 920-929. Peer-reviewed.
 
Management of Severe Portopulmonary Hypertension With Dual Oral Therapy Before Liver Transplantation.
Vionnet J., Yerly P., Aubert J.D., Pascual M., Aldenkortt F., Berney T., Giostra E., Moradpour D., Schiffer E., 2018/05. Transplantation, 102 (5) pp. e194. Peer-reviewed.
 
Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland.
Fraga M., Doerig C., Moulin H., Bihl F., Brunner F., Müllhaupt B., Ripellino P., Semela D., Stickel F., Terziroli Beretta-Piccoli B. et al., 2018/04. Liver international, 38 (4) pp. 619-626. Peer-reviewed.
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.
Bartenschlager R., Baumert T.F., Bukh J., Houghton M., Lemon S.M., Lindenbach B.D., Lohmann V., Moradpour D., Pietschmann T., Rice C.M. et al., 2018/03/15. Virus research, 248 pp. 53-62. Peer-reviewed.
 
Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.
Wu X., Dao Thi V.L., Liu P., Takacs C.N., Xiang K., Andrus L., Gouttenoire J., Moradpour D., Rice C.M., 2018/02. Gastroenterology, 154 (3) pp. 663-674.e7. Peer-reviewed.
Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis.
Papadakis G.E., Lamine F., Chtioui H., Moschouri E., Christinet M.F., Marino L., Favre L., Sciarra A., Sempoux C., Schneider A. et al., 2018/02. Thyroid, 28 (2) pp. 276-278. Peer-reviewed.
 
Trends in hepatitis C-related mortality in Switzerland.
Keiser O., Giudici F., Müllhaupt B., Junker C., Dufour J.F., Moradpour D., Bruggmann P., Terziroli B., Semela D., Brezzi M. et al., 2018/02. Journal of viral hepatitis, 25 (2) pp. 152-160. Peer-reviewed.
Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122.
Saleh M., Rüschenbaum S., Welsch C., Zeuzem S., Moradpour D., Gouttenoire J., Lange C.M., 2018. Frontiers in microbiology, 9 p. 2949. Peer-reviewed.
 
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.
Farhat R., Ankavay M., Lebsir N., Gouttenoire J., Jackson C.L., Wychowski C., Moradpour D., Dubuisson J., Rouillé Y., Cocquerel L., 2018/01. Cellular microbiology, 20 (1) pp. 1-11. Peer-reviewed.
Targeting Endoplasmic Reticulum and/or Mitochondrial Ca2+ Fluxes as Therapeutic Strategy for HCV Infection.
Scrima R., Piccoli C., Moradpour D., Capitanio N., 2018. Frontiers in chemistry, 6 p. 73. Peer-reviewed.
 
06: Visualization of hepatitis E virus RNA and proteins in the human liver
Lenggenhager D, Gouttenoire J., Malehmir M., Bawohl M., Honcharova -Biletska H., Kreutzer S., Semela D., Neuweiler J., Hürlimann S., Aepli P. et al., 2017/10/20. pp. 571-572 dans Swiss Pathology Days, Der Pathologe.
 
A systematic review and meta-analysis of HCV clearance.
Gauthiez E., Habfast-Robertson I., Rüeger S., Kutalik Z., Aubert V., Berg T., Cerny A., Gorgievski M., George J., Heim M.H. et al., 2017/10. Liver international, 37 (10) pp. 1431-1445. Peer-reviewed.
 
Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
Vionnet J., Pascual M., Testoni B., Combet C., Godat S., Vijgen S., Aubert V., Rubbia-Brandt L., Zoulim F., Moradpour D., 2017/09/16. Hepatology, 67 (2) pp. 791-793 . Peer-reviewed.
 
Visualization of hepatitis E virus RNA and proteins in the human liver.
Lenggenhager D., Gouttenoire J., Malehmir M., Bawohl M., Honcharova-Biletska H., Kreutzer S., Semela D., Neuweiler J., Hürlimann S., Aepli P. et al., 2017/09. Journal of hepatology, 67 (3) pp. 471-479. Peer-reviewed.
 
Hépatite E : qui cherche… trouve
Moradpour D., Frossard J.L., 2017/08/30. Revue medicale suisse, 13 (572) pp. 1451-1452. Peer-reviewed.
 
Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy.
van Eijk JJJ, Dalton H.R., Ripellino P., Madden R.G., Jones C., Fritz M., Gobbi C., Melli G., Pasi E., Herrod J. et al., 2017/08/29. Neurology, 89 (9) pp. 909-917. Peer-reviewed.
 
Akute und chronische Hepatitis E []
Fraga M., Gouttenoire J., Sahli R., Moradpour D., 2017/07. Therapeutische Umschau. Revue therapeutique, 74 (3) pp. 109-113. Peer-reviewed.
 
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Béguelin C., Friolet N., Moradpour D., Sahli R., Suter-Riniker F., Lüthi A., Cavassini M., Günthard H.F., Battegay M., Bernasconi E. et al., 2017/05/01. Clinical infectious diseases, 64 (9) pp. 1275-1278. Peer-reviewed.
 
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
Béguelin C., Moradpour D., Sahli R., Suter-Riniker F., Lüthi A., Cavassini M., Günthard H.F., Battegay M., Bernasconi E., Schmid P. et al., 2017/02. Journal of hepatology, 66 (2) pp. 297-303. Peer-reviewed.
 
A European survey of perendoscopic treatment of biliary complications in patients with alveolar echinococcosis.
Ambregna S., Koch S., Sulz M.C., Grüner B., Öztürk S., Chevaux J.B., Sulima M., de Gottardi A., Napoléon B., Abergel A. et al., 2017/01. Expert review of anti-infective therapy, 15 (1) pp. 79-88. Peer-reviewed.
 
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
Fraga M., Fournier N., Safroneeva E., Pittet V., Godat S., Straumann A., Nydegger A., Vavricka S.R., Moradpour D., Schoepfer A.M. et al., 2017/01. European journal of gastroenterology & hepatology, 29 (1) pp. 91-97. Peer-reviewed.
 
Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
Moradpour D., Grakoui A., Manns M.P., 2016/10. Journal of hepatology, 65 (1 Suppl) pp. S143-S155. Peer-reviewed.
 
Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
Gouttenoire J., Szkolnicka D., Moradpour D., 2016/10. Gut, 65 (10) pp. 1583-1584. Peer-reviewed.
 
Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
Giudici F., Bertisch B., Negro F., Stirnimann G., Müllhaupt B., Moradpour D., Cerny A., Keiser O., Swiss Hepatitis C Cohort Study, 2016/09. Journal of viral hepatitis, 23 (9) pp. 697-707. Peer-reviewed.
Amyloïdose héréditaire à transthyrétine [Transthyretin-related hereditary amyloidosis]
Vionnet J., Pascual M., Kuntzer T., Yerly P., Moradpour D., 2016/08/31. Revue medicale suisse, 12 (528) pp. 1434-1440. Peer-reviewed.
 
Gastroentérite à éosinophiles [Eosinophilic gastrointestinal disorders]
Burgmann K., Brunel C., Sempoux C., Ribi C., Godat S., Moradpour D., Schoepfer A.M., 2016/08/31. Revue medicale suisse, 13 (528) pp. 1430-1433. Peer-reviewed.
Transplantation fécale : les faits et les espoirs démesurés ?
Frossard J.L., Moradpour D., 2016/08/31. Revue medicale suisse, 12 (528) p. 1403. Peer-reviewed.
 
Hepatitis E virus infection as a direct cause of neuralgic amyotrophy.
Silva M., Wicki B., Tsouni P., Cunningham S., Doerig C., Zanetti G., Aubert V., Sahli R., Moradpour D., Kuntzer T., 2016/08. Muscle & nerve, 54 (2) pp. 325-327. Peer-reviewed.
 
Update on hepatitis E virology: Implications for clinical practice.
Debing Y., Moradpour D., Neyts J., Gouttenoire J., 2016/07. Journal of hepatology, 65 (1) pp. 200-212. Peer-reviewed.
 
Hepatitis E
Béguelin Charles, Fraga Montserrat, Wandeler Gilles, Sahli Roland, Rauch Andri, Moradpour Darius, 2016/06/14. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 16 (24) pp. 510-514. Peer-reviewed.
 
Cell-free expression, purification, and membrane reconstitution for NMR studies of the nonstructural protein 4B from hepatitis C virus.
Fogeron M.L., Jirasko V., Penzel S., Paul D., Montserret R., Danis C., Lacabanne D., Badillo A., Gouttenoire J., Moradpour D. et al., 2016/06. Journal of biomolecular NMR, 65 (2) pp. 87-98. Peer-reviewed.
Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania.
Winter A., Letang E., Vedastus Kalinjuma A., Kimera N., Ntamatungiro A., Glass T., Moradpour D., Sahli R., Le Gal F., Furrer H. et al., 2016/03. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 46 pp. 8-10. Peer-reviewed.
 
A mouse model for hepatitis E virus infection.
Gouttenoire J., Moradpour D., 2016. Journal of Hepatology, 64 (5) pp. 1003-1005. Peer-reviewed.
Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.
Bertisch B., Giudici F., Negro F., Moradpour D., Müllhaupt B., Moriggia A., Estill J., Keiser O., Swiss Hepatitis C Cohort Study, 2016. PloS one, 11 (5) pp. e0155464. Peer-reviewed.
 
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
Mallet V., van Bömmel F., Doerig C., Pischke S., Hermine O., Locasciulli A., Cordonnier C., Berg T., Moradpour D., Wedemeyer H. et al., 2016. Lancet. Infectious Diseases, 16 (5) pp. 606-617. Peer-reviewed.
 
Reply.
Dao Thi V.L., Debing Y., Wu X., Rice C.M., Neyts J., Moradpour D., Gouttenoire J., 2016. Gastroenterology, 150 (7) pp. 1690-1691. Peer-reviewed.
 
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi V.L., Debing Y., Wu X., Rice C.M., Neyts J., Moradpour D., Gouttenoire J., 2016. Gastroenterology, 150 (1) pp. 82-85.e4. Peer-reviewed.
 
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Vionnet J., Saouli A.C., Pascual M., Stucker F., Decosterd L.A., Moradpour D., Chtioui H., 2016. Journal of Hepatology, 65 (5) pp. 1063-1065. Peer-reviewed.
 
Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
Béguelin C., Vazquez M., Moradpour D., Sahli R., Suter F., Rauch A., Wandeler G., 2016. Aids (london, England), 30 (3) pp. 530-533. Peer-reviewed.
 
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
Wang H., El Maadidi S., Fischer J., Grabski E., Dickhöfer S., Klimosch S., Flannery S.M., Filomena A., Wolz O.O., Schneiderhan-Marra N. et al., 2015. Hepatology (baltimore, Md.), 62 (5) pp. 1375-1387.
 
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.
Terczyńska-Dyla E., Bibert S., Duong F.H., Krol I., Jørgensen S., Collinet E., Kutalik Z., Aubert V., Cerny A., Kaiser L. et al., 2015..
 
Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials.
Deltenre P., Trépo E., Rudler M., Monescillo A., Fraga M., Denys A., Doerig C., Fournier N., Moreno C., Moradpour D. et al., 2015. European Journal of Gastroenterology and Hepatology, 27 (9) pp. e1-e9. Peer-reviewed.
 
Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
Welsch C., Haselow K., Gouttenoire J., Schneider M., Morikawa K., Martinez Y., Susser S., Sarrazin C., Zeuzem S., Antes I. et al., 2015. Journal of Hepatology, 62 (4) pp. 779-784. Peer-reviewed.
 
Hépatite C: 25 ans de progrès avec encore des défis majeurs [Hepatitis C: 25 years of progress with still major challenges].
Moradpour D., Frossard J.L., 2015. Revue Médicale Suisse, 11 (484) pp. 1579-1580.
 
Hépatite C: information pour les patients [Hepatitis C: patient information].
Müllhaupt B., Moradpour D., 2015. Revue Médicale Suisse, 11 (471) pp. 907-908.
 
Hépatite C: traitement actuel [Hepatitis C: current therapy].
Moradpour D., Müllhaupt B., 2015. Revue Médicale Suisse, 11 (471) pp. 902-906.
 
Hépatite C: épidémiologie, histoire naturelle et diagnostic [Hepatitis C: epidemiology natural course and diagnosis].
Moradpour D., Müllhaupt B., 2015. Revue Médicale Suisse, 11 (471) pp. 896-901.
 
Impact of common risk factors of fibrosis progression in chronic hepatitis C.
Rüeger S., Bochud P.Y., Dufour J.F., Müllhaupt B., Semela D., Heim M.H., Moradpour D., Cerny A., Malinverni R., Booth D.R. et al., 2015. Gut, 64 (10) pp. 1605-1615. Peer-reviewed.
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Vionnet J., Pascual M., Chtioui H., Giostra E., Majno P.E., Decosterd L.A., Moradpour D., 2015. BMC Gastroenterology, 15 (1) p. 38. Peer-reviewed.
 
Systematic review with meta-analysis: self-expanding metal stents in patients with cirrhosis and severe or refractory oesophageal variceal bleeding.
Marot A., Trépo E., Doerig C., Moreno C., Moradpour D., Deltenre P., 2015. Alimentary Pharmacology and Therapeutics, 42 (11-12) pp. 1250-1260. Peer-reviewed.
 
Wheat germ cell-free expression: Two detergents with a low critical micelle concentration allow for production of soluble HCV membrane proteins.
Fogeron M.L., Badillo A., Jirasko V., Gouttenoire J., Paul D., Lancien L., Moradpour D., Bartenschlager R., Meier B.H., Penin F. et al., 2015. Protein Expression and Purification, 105 pp. 39-46. Peer-reviewed.
 
Nouveaux traitements de l'hépatite C: aspects pharmacologiques et potentiel d'interaction [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Chtioui H., Buclin T., Moradpour D., 2014/09. Revue Médicale Suisse, 10 (440) pp. 1600-4, 1606.
Actualités diagnostiques et thérapeutiques dans le domaine de l'encéphalopathie hépatique [Hepatic encephalopathy: recent developments].
Deltenre P., Moradpour D., 2014. Revue Médicale Suisse, 10 (440) pp. 1612, 1614-1612, 1616. Peer-reviewed.
Aminoterminal amphipathic α-helix AH1 of hepatitis C virus nonstructural protein 4B possesses a dual role in RNA replication and virus production.
Gouttenoire J., Montserret R., Paul D., Castillo R., Meister S., Bartenschlager R., Penin F., Moradpour D., 2014. Plos Pathogens, 10 (11) pp. e1004501. Peer-reviewed.
 
Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.
Maillard M.H., Bortolotti M., Vader J.P., Mottet C., Schoepfer A., Gonvers J.J., Burnand B., Froehlich F., Michetti P., Pittet V. et al., 2014. Journal of Crohn's and Colitis, 8 (8) pp. 825-834.
 
Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.
Maillard M.H., Bortolotti M., Vader J.P., Mottet C., Schoepfer A., Gonvers J.J., Burnand B., Froehlich F., Michetti P., Pittet V. et al., 2014/01. Journal of Crohn's and Colitis, 8 (8) pp. 825-834.
 
Bridging basic science and clinical research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis.
Boettler T., Moradpour D., Thimme R., Zoulim F., 2014. Journal of Hepatology, 61 (3) pp. 696-705. Peer-reviewed.
Café et pancréas: la demi-vie de la vérité en médecine [Coffee and the pancreas: a half life of medical truth].
Frossard J.L., Moradpour D., 2014. Revue Médicale Suisse, 10 (440) p. 1579. Peer-reviewed.
Clinical significance of the CCR5delta32 allele in hepatitis C.
Morard I., Clément S., Calmy A., Mangia A., Cerny A., De Gottardi A., Gorgievski M., Heim M., Malinverni R., Moradpour D. et al., 2014. Plos One, 9 (9) pp. e106424. Peer-reviewed.
 
Determinants for membrane association of the hepatitis C virus NS2 protease domain.
Lange C.M., Bellecave P., Dao Thi V.L., Tran H.T., Penin F., Moradpour D., Gouttenoire J., 2014. Journal of Virology, 88 (11) pp. 6519-6523. Peer-reviewed.
 
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.
Frei P., Leucht A.K., Held U., Kofmehl R., Manser C.N., Schmitt J., Mertens J., Rau M., Baur K., Gerlach T. et al., 2014. Liver International, 34 (4) pp. 551-557. Peer-reviewed.
GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.
Masin M., Vazquez J., Rossi S., Groeneveld S., Samson N., Schwalie P.C., Deplancke B., Frawley L.E., Gouttenoire J., Moradpour D. et al., 2014. Cancer and Metabolism, 2 p. 11.
 
Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie [Hepatitis B and C: From molecular virology to new antiviral therapies (part 1)].
Thimme R., Heim M., Baumert T.F., Nassal M., Moradpour D., 2014. Deutsche Medizinische Wochenschrift, 139 (13) pp. 655-659. Peer-reviewed.
 
Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie [Hepatitis B and C: from molecular virology to new antiviral therapies (part 2)].
Thimme R., Heim M., Baumert T.F., Nassal M., Moradpour D., 2014. Deutsche Medizinische Wochenschrift (1946), 139 (15) pp. 778-782.
 
Hepatitis C Virus Infection and Kidney Transplantation in 2014: What's New?
Baid-Agrawal S., Pascual M., Moradpour D., Somasundaram R., Muche M., 2014. American Journal of Transplantation, 14 (10) pp. 2206-2220.
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index.
Hoggart C.J., Venturini G., Mangino M., Gomez F., Ascari G., Zhao J.H., Teumer A., Winkler T.W., Ternikova N., Luan J. et al., 2014. PLoS Genetics, 10 (7) pp. e1004508.
 
NS2 Proteins of GB Virus B and Hepatitis C Virus Share Common Protease Activities and Membrane Topologies.
Boukadida C., Marnata C., Montserret R., Cohen L., Blumen B., Gouttenoire J., Moradpour D., Penin F., Martin A., 2014. Journal of Virology, 88 (13) pp. 7426-7444. Peer-reviewed.
 
Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression.
Quarato G., Scrima R., Ripoli M., Agriesti F., Moradpour D., Capitanio N., Piccoli C., 2014. Biochemical Pharmacology, 89 (4) pp. 545-556. Peer-reviewed.
 
Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.
Morikawa K., Gouttenoire J., Hernandez C., Dao Thi V.L., Tran H.T., Lange C.M., Dill M.T., Heim M.H., Donzé O., Penin F. et al., 2014. Hepatology, 59 (2) pp. 423-433. Peer-reviewed.
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes
Terczyńska-Dyla E., Bibert S., Duong F.H., Krol I., Jørgensen S., Collinet E., Kutalik Z., Aubert V., Cerny A., Kaiser L. et al., 2014. Nature Communications, 5 p. 5699. Peer-reviewed.
 
Vitamin D Receptor and Jak-STAT Signaling Crosstalk Results in Calcitriol-Mediated Increase of Hepatocellular Response to IFN-α.
Lange C.M., Gouttenoire J., Duong F.H., Morikawa K., Heim M.H., Moradpour D., 2014. Journal of Immunology, 192 (12) pp. 6037-6044. Peer-reviewed.
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.
Schnegg A., Bürgisser P., André C., Kenfak-Foguena A., Canellini G., Moradpour D., Abravanel F., Izopet J., Cavassini M., Darling K.E., 2013. Plos One, 8 (5) pp. e62980.
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Esser-Nobis K., Romero-Brey I., Ganten T.M., Gouttenoire J., Harak C., Klein R., Schemmer P., Binder M., Schnitzler P., Moradpour D. et al., 2013. Hepatology, 57 (3) pp. 953-963. Peer-reviewed.
 
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.
Lange C.M., Bibert S., Dufour J.F., Cellerai C., Cerny A., Heim M.H., Kaiser L., Malinverni R., Müllhaupt B., Negro F. et al., 2013. Journal of Hepatology, 59 (3) pp. 504-509.
 
Differential impact of common risk factors of fibrosis progression in chronic hepatitis C
Rueger S., Bochud P.Y., Dufour J.F., Mullhaupt B., Semela D., Heim M.H., Moradpour D., Cerny A., Malinverni R., Kutalik Z. et al., 2013. pp. 1295A-1296A dans 64th Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases, Hepatology.
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development.
Lange C.M., Miki D., Ochi H., Nischalke H.D., Bojunga J., Bibert S., Morikawa K., Gouttenoire J., Cerny A., Dufour J.F. et al., 2013. Plos One, 8 (5) pp. e64053. Peer-reviewed.
 
Hepatitis C virus proteins: from structure to function.
Moradpour D., Penin F., 2013. Current Topics in Microbiology and Immunology, 369 pp. 113-142.
Hepatologie: Wichtiges zu chronischen Hepatitis C
Müllhaupt B., Moradpour D., 2013. Swiss Medical Forum = Schweizerisches Medizin-Forum, 13 (3) pp. 28-30.
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.
Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., Duong F.H., Gerlach T., Malinverni R., Moradpour D. et al., 2013. Journal of Experimental Medicine, 210 (6) pp. 1109-1116. Peer-reviewed.
 
IL28B Rna Expression Depends On A Novel Tt/-G Polymorphism Associated With Improved Hcv Clearance Prediction
Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., Duong F.H., Gerlach T., Malinverni R., Moradpour D. et al., 2013. pp. S571 dans Abstracts of The International Liver Congress 2013 - 48th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
 
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
Rau M., Stickel F., Russmann S., Manser C.N., Becker P.P., Weisskopf M., Schmitt J., Dill M.T., Dufour J.F., Moradpour D. et al., 2013. Journal of Hepatology, 58 (4) pp. 669-675.
 
Mise à jour sur l'hépatite E [An update on hepatitis E].
Hiroz P., Gouttenoire J., Dao Thi V.L., Sahli R., Telenti A., Moradpour D., Doerig C., 2013. Revue Médicale Suisse, 9 (396) pp. 1594-1598.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.
Stickel F., Worni M., Pache I., Moradpour D., Helbling B., Borovicka J., Gerlach T.J., 2013. American Journal of Gastroenterology, 108 (7) pp. 1176-1178.
 
Penetrating or Stricturing Diseases are the Major Determinants of Time to First and Repeat Resection Surgery in Crohn's Disease.
Pittet V., Rogler G., Michetti P., Fournier N., Vader J.P., Schoepfer A., Mottet C., Burnand B., Froehlich F., 2013. Digestion, 87 (3) pp. 212-221.
Progrès et nouveaux défis dans l'hépatite C [Progress and new challenges in hepatitis C].
Moradpour D., Frossard J.L., 2013. Revue Médicale Suisse, 9 (396) pp. 1563-1564. Peer-reviewed.
 
Targeting mitochondria in the infection strategy of the hepatitis C virus.
Quarato G., Scrima R., Agriesti F., Moradpour D., Capitanio N., Piccoli C., 2013. International Journal of Biochemistry and Cell Biology, 45 (1) pp. 156-166.
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
Patin E., Kutalik Z., Guergnon J., Bibert S., Nalpas B., Jouanguy E., Munteanu M., Bousquet L., Argiro L., Halfon P. et al., 2012/11. Gastroenterology, 143 (5) pp. 1244-52.e1-12. Peer-reviewed.
Hypertension portale et prise en charge de l'ascite [Management of ascites due to portal hypertension]
Godat S., Antonino A.T., Dehlavi M.A., Moradpour D., Doerig C., 2012/09/05. Revue medicale suisse, 8 (352) pp. 1665-1668. Peer-reviewed.
 
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection.
Girardin F., Daali Y., Gex-Fabry M., Rebsamen M., Roux-Lombard P., Cerny A., Bihl F., Binek J., Moradpour D., Negro F. et al., 2012/08. Journal of viral hepatitis, 19 (8) pp. 568-573. Peer-reviewed.
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
Manns M.P., Gane E., Rodriguez-Torres M., Stoehr A., Yeh C.T., Marcellin P., Wiedmann R.T., Hwang P.M., Caro L., Barnard R.J. et al., 2012/07. Hepatology (baltimore, Md.), 56 (3) pp. 884-893.
A comparison of three anti-HEV IgG EIA screening kits and one confirmatory immunodot assay in blood donor samples in Switzerland
Schnegg A., Bürgisser P., André C., Kenfak-Foguena A., Canellini G., Moradpour D., Darling K.E.A., Cavassini M., 2012. dans ICAAC 2012, 52nd of the Interscience Conference on Antimicrobial Agents and Chemotherapy.
 
A European field study of the efficacy and safety of tenofovir disoproxil fumarate as monotherapy in patients with prior failure to other nucleoside/nucleotide analogues
van Bömmel F., Zoutendijk R., de Man R., Bronowicki J.P., Rutter K., Ferenci P, Janssen H., Fülöp B., Brodzinski A., Wiegand J. et al., 2012. pp. S216 dans 47th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
 
A functional link between vitamin D receptor and Jak-STAT signaling results in synergistic hepatocellular response to calcitriol and interferon-
Lange C.M., Gouttenoire J., Duong F.H.T., Morikawa K., Heim M.H., Moradpour D., 2012. pp. S54 dans 47th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.
Lange C.M., Bibert S., Kutalik Z., Burgisser P., Cerny A., Dufour J.F., Geier A., Gerlach T.J., Heim M.H., Malinverni R. et al., 2012. Plos One, 7 (7) pp. e40159.
 
Analysis of HCV resistance to silibinin in vitro and in vivo reveals a novel antiviral mechanism targeting nonstructural protein 4B
Esser-Nobis K., Romero-Brey I., Ganten T.M., Gouttenoire J., Klein R., Schremmer P., Binder M., Schnitzler P., Moradpour D., Bartenschlager R. et al., 2012. dans HCV 2012, 19th International Symposium on Hepatitis C Virus and Related Viruses.
 
Anti-TNF Therapy in the Swiss Inflammatory Bowel Disease G8 Cohort
Hiroz P., Fournier N., Safroneeva E., Moradpour D., Schoepfer A.M., 2012. pp. 12S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Calprotectine fécale: outil diagnostique dans les maladies inflammatoires chroniques de l'intestin [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].
Fraga M., Godat S., Nydegger A., Moradpour D., Schoepfer A.M., 2012. Revue Médicale Suisse, 8 (352) pp. 1669-1673.
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.
Kuske L., Mensen A., Mã Llhaupt B., Negro F., Semela D., Moradpour D., Malã P., Heim M., Malinverni R., Cerny A. et al., 2012. Swiss Medical Weekly, 142 pp. w13651.
 
Determinants for Membrane Association of the HCV NS2 Protease Domain
Kennel A., Penin F., Moradpour D., Gouttenoire J., 2012. dans HCV 2012, 19th International Symposium on Hepatitis C Virus and Related Viruses.
 
EASL Clinical Practice Guidelines: Wilson's disease.
European Association for Study of Liver, 2012. Journal of Hepatology, 56 (3) pp. 671-685.
 
Establishment of HEV RNA reverse transcriptase PCR assays for the diagnosis of acute and chronic hepatitis E
Doerig C., Antonino A.T., Müllhaupt B., Telenti A., Moradpour D., Sahli R., 2012. pp. 3S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Frequency and Type of Side Effects of Immunomodulating Medication in the Swiss Inflammatory Bowel Disease Cohort
Godat S., Fournier N., Pittet V., Safroneeva E., Moradpour D., Schoepfer A., 2012. pp. S249 dans DDW 2012, Digestive Disease Week, Gastroenterology.
 
Frequency and type of side effects of immunomodulating medication in the Swiss Inflammatory Bowel Disease Cohort.
Godat S., Pittet V., Fournier N., Safroneeva E., Moradpour D., Schoepfer A.M., 2012. pp. 12S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
GB virus B NS2 is an autoprotease with similar membrane topology as HCV NS2
Boukadida C., Marnata C., Cohen L., Fogeron M.L., Gouttenoire J., Moradpour D., Penin F., Martin A., 2012. dans HCV 2012, 19th International Symposium on Hepatitis C Virus and Related Viruses.
 
Genetic association analyses reveal a role for vitamin D insufficiency in hepatitis C virus-associated hepatocellular carcinoma development
Lange C.M., Miki D., Ochi H., Nischalke H.D., Bojunga J., Bibert S., Morikawa K., Gouttenoire J., Cerny A., Dufour J.F. et al., 2012., Congrès annuel de la SGG pp. 4S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Genome-wide association study identifies variants associated with liver fibrosis progression in HCV-infected patients
Patin E., Kutalik Z., Guergnon J., Bibert S., Nalpas B., Jouanguy E., Munteanu M., Bousquet L., Argiro I., Halfon P. et al., 2012. pp. S551 dans 47th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
 
HBV-HCV coinfection: a novel model system reveals insights into immunological mechanisms of viral interference
Lass C., Präg C., Grimm D., Gouttenoire J., Lohmann V., Köck J., Nassal M., Blum H.E., Bartenschlager R., Moradpour D. et al., 2012. pp. S310 dans 47th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
 
HBV-HCV coinfection: immune-mediated mechanisms of viral interference
Lass C, Präg C, Grimm D, Gouttenoire J, Lohmann V, Köck J, Nassal M, Blum H.E., Bartenschlager R., Moradpour D. et al., 2012. dans HCV 2012, 19th International Symposium on Hepatitis C Virus and Related Viruses.
 
Hépatite C : avancées thérapeutiques
Schneider M.P., Genre N., Reymermier M., Bugnon O., Moradpour D., 2012. PharmaJournal, 150 (24) pp. 5-9.
 
Identification of GPx8 as a novel cellular substrate of the hepatitis C virus NS3-4A protease
Morikawa K., Gouttenoire J., Tran H.T.L., Heim M.H., Quadroni M., Moradpour D., 2012. pp. 5S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Identification of GPx8 as a novel cellular substrate of the hepatitis C virus NS3-4A protease
Morikawa K., Gouttenoire J., Tran H.T.L., Penin F., Heim M.H., Quadroni M., Moradpour D., 2012. pp. 707A dans 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology.
 
Identification of GPx8 as a proviral host factor cleaved by the HCV NS3-4A protease
Morikawa K, Gouttenoire J., Tran H.T.L., Heim M.H., Quadroni M., Moradpour D., 2012. dans HCV 2012, 19th International Symposium on Hepatitis C Virus and Related Viruses.
Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands.
Wölk B., Trautwein C., Büchele B., Kersting N., Blum H.E., Rammensee H.G., Cerny A., Stevanovic S., Moradpour D., Brass V., 2012. Plos One, 7 (e29286) pp. 1-7.
 
Ikterus
Moradpour D., Blum H.E., 2012. pp. 752-791 dans Battegay E. (eds.) Siegenthalers Differenzialdiagnose : Innere Krankheiten - vom Symptom zur Diagnose chap. 25, Thieme.
 
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
Bochud P.Y., Bibert S., Kutalik Z., Patin E., Guergnon J., Nalpas B., Goossens N., Kuske L., Müllhaupt B., Gerlach T. et al., 2012. Hepatology, 55 (2) pp. 384-394.
 
Immunosuppression in hepatitis C virus-infected patients after kidney transplantation.
Manuel O., Baid-Agrawal S., Moradpour D., Pascual M., 2012. Contributions to Nephrology, 176 pp. 97-107.
 
Impact of genetic concentrative nucleoside transporter variants on PEG-interferon/ribavirin therapy response and ribavirin serum levels in hepatitis C patients
Rau M., Weisskopf M., Stickel F., Schmitt J., Russmann S., Dill M.T., Dufour J.F., Moradpour D., Negro F., Semela D. et al., 2012. pp. S455 dans 47th Annual Meeting of the European Association for the Study of the Liver, Journal of Hepatology.
 
Impact of genetic SLC28 transporter and ITPA variants on ribavirin 21 serum level, hemoglobin drop and therapeutic response in patients with HCV infection
Rau M., Stickel F., Russmann S., Weisskopf M., Schmitt J., Dill M.T., Dufour J.F., Moradpour D., Semela D., Müllhaupt B. et al., 2012. pp. S7 dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
La maladie alcoolique du foie: une autre maladie négligée [Alcoholic liver disease: another neglected disease?].
Hadengue A., Moradpour D., 2012. Revue Médicale Suisse, 8 (352) pp. 1643-1644. Peer-reviewed.
 
Long diagnostic delay in Crohn's disease is associated with complicated disease course and increased operation rate
Dehlavi M.A., Vavricka S.R., Pittet V., Fournier N., Safroneeva E., Rogler G., Moradpour D., Schoepfer A., 2012. pp. S257 dans DDW 2012, Digestive Disease Week, Gastroenterology.
 
Molecular determinants for membrane association of the hepatitis C virus NS2 protease domain
Lange C.M., Bellecave P., Kennel A., Penin F., Moradpour D., Gouttenoire J., 2012. pp. 3S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Primary sclerosing cholangitis in the Swiss IBD Cohort Study: prevalence, patient characteristics, and disease course.
Fraga M., Fournier N., Safroneeva E., Maradpour D., Vavricka S.R., Schoepfer A.M., 2012. pp. 19S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Role of CCR5 genetic polymorphisms in clinical and histological outcomes of hepatitis C
Morard I., Pascarella S., Calmy A., Mangia A., Clément S., Cerny A., Dufour J.F., Gorgievski M., Heim M., Malinverni R. et al., 2012. pp. 15S dans Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society of Visceral Surgery, Swiss Association of the Study of the Liver and Swiss Society of Clinical Nutrition, Swiss Medical Weekly.
 
Schmerzen im Bereich des Abdomens
Moradpour D., Blum H.E., 2012. pp. 272-317 dans Battegay E. (eds.) Siegenthalers Differenzialdiagnose : Innere Krankheiten - vom Symptom zur Diagnose chap. 7, Thieme.
 
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange C.M., Kutalik Z., Morikawa K., Bibert S., Cerny A., Dollenmaier G., Dufour J.F., Gerlach T.J., Heim M.H., Malinverni R. et al., 2012. Hepatology, 55 (4) pp. 1038-1047. Peer-reviewed.
 
The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
Quarato G., D'Aprile A., Gavillet B., Vuagniaux G., Moradpour D., Capitanio N., Piccoli C., 2012. Hepatology, 55 (5) pp. 1333-1343.
 
The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Baur K., Mertens J.C., Schmitt J., Iwata R., Stieger B., Frei P., Seifert B., Bischoff Ferrari H.A., von Eckardstein A., Müllhaupt B. et al., 2012. Antiviral Therapy, 17 (3) pp. 541-547.
 
Traitement des dyslipidémies et atteinte hépatique [Lipid-lowering treatment and liver dysfunction].
Gencer B., Moradpour D., Rodondi N., 2012. Revue Médicale Suisse, 8 (331) pp. 507-512.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Swiss Association for the Study of the Liver, 2012. Swiss Medical Weekly, 142 pp. w13516.
 
Oesophagite a eosinophiles: mise a jour 2011 [Eosinophilic esophagitis: update 2011]
Godat S., Moradpour D., Schoepfer A., 2011/09/07. Revue medicale suisse, 7 (307) pp. 1678-1680, 1682. Peer-reviewed.
Traitement et prophylaxie de la Maladie ThromboEmbolique Veineuse (MTEV)
Centre hospitalier universitaire vaudois, Policlinique médicale universitaire (Lausanne) , 2011/05. 2 p..
NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly.
Popescu C.I., Callens N., Trinel D., Roingeard P., Moradpour D., Descamps V., Duverlie G., Penin F., Héliot L., Rouillé Y. et al., 2011/02. Plos Pathogens, 7 (e1001278) pp. 1-20.
 
A large-scale genetic validation study coupled with in vitro analyses reveal a role for vitamin Dsignaling in the pathogenesis and response to treatment of hepatitis C virus infection
Lange C.M., Bibert S., Kutalik Z., Morikawa K., Cerny A., Dufour J.F., Gerlach T.J., Heim M.H., Malinverni R., Muellhaupt B. et al., 2011. pp. S537 dans 46th Annual Meeting of the European Association for the Study of the Liver (EASL), Journal of Hepatology. Peer-reviewed.
Actualités en gastroentérologie et hépatologie [Highlights in gastroenterology and hepatology 2010].
Schoepfer A., Pache I., Nichita C., Dorta G., Moradpour D., 2011. Revue Médicale Suisse, 7 (277) pp. 25-29. Peer-reviewed.
 
Age above 60 years is not a negative predictive factor for combined antiviral therapy with pegylated interferon alpha and ribavirin in hepatitis C patients
Frei P., Leucht A.K., Held U., Kofmehl R., Schmitt J., Rau M., Gerlach T., Negro F., Heim M.H., Moradpour D. et al., 2011. pp. 826A dans 62nd Annual Meeting of the American Association for the Study of Liver Diseases, Hepatology. Peer-reviewed.
 
Analysis of the topology and membrane association of GB virus B NS2 protein Moradpour
Moradpour D., Gouttenoire J., 2011. dans 18th International Sympsium on Hepatitis C Virus and Related Viruses.
 
Characterization of a major V3 duplication in the NS5A region of genotype 1b HCV by quasispecies analysis in a French multicenter study
Le Guillou-Guillemette H., Bouthry E., Pivert A., Rosenberg A., Alain S., Thibault V., Abravanel F., Minjolle-Cha S., Andre-Garnier E., Moradpour D. et al., 2011. pp. S322 dans 46th Annual Meeting of the European Association for the Study of the Liver (EASL), Journal of Hepatology. Peer-reviewed.
Consequences of the multipatient use of a single-patient capillary blood sampling device (CBSD)
Staeger P., Ninane F., Mazzolai L., Moradpour D., Wasserfallen J., Masserey E., Senn L., Zanetti G., 2011. pp. P92 dans ICPIC 2011, 1st International Conference on Prevention and Infection Control, BMC Proceedings.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University